- Poster presentation
- Open access
- Published:
Influence of vasopressor agent in pediatric septic shock mortality
Critical Care volume 15, Article number: P16 (2011)
Objective
To clarify the impact of the choice of vasopressor support on mortality in pediatric septic shock (SS).
Methods
A retrospective study based on the institutional database analyzing 1,050 patients admitted from October 1999 to January 2005. We studied children with SS after the neonatal period admitted to the pediatric intensive care (PICU) and we assessed the vasopressor support in the first 24 hours, PICU and hospital (HSP) length of stay (LOS), number of vasoactive drugs used, association between drugs and HSP mortality.
Results
There were 101 consecutive patients with SS, mean age 41 months (95% CI = 30 to 52 months); mean of PICU LOS 16.73 days (95% CI = 11.18 to 22.28) and hospital LOS 55.46 days (95% CI = 43.16 to 67.75). PICU mortality was 32% and HSP mortality after PICU discharge was 10.8%. Of these, 33% patients received dobutamine and 26% patients dopamine as the only vasoactive drug. Dopamine plus dobutamine was used in 17.8%; dobutamine plus norepinephrine in 18% and dopamine plus norephinephrine in 3.9%. The HSP mortality associated with dobutamine was 29.4%; dopamine 53.8%; dopamine plus dobutamine 50%; dopamine plus norepinephrine 25%. The dopamine and dopamine plus dobutamine groups had higher hospital mortality (66% vs. 34%). Dopamine was associated with hypertensive state (odds ratio, 0.433; 95% CI = 0.192 to 0.976; P = 0.047), hypoxemia (odds ratio, 0.190; 95% CI = 0.040 to 0.909) and mechanical ventilation utilization (odds ratio, 2.625; 95% CI = 1.085 to 6.327; P = 0.035).
Conclusion
Adrenergic support for pediatric patients with SS remains controversial. A prospective randomized controlled trial will be important to determine which subgroups of SS patients will benefit most with each drug.
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Mangia, C., Jose, L., Monteiro, F. et al. Influence of vasopressor agent in pediatric septic shock mortality. Crit Care 15 (Suppl 2), P16 (2011). https://doi.org/10.1186/cc10164
Published:
DOI: https://doi.org/10.1186/cc10164